MRNA RSI Chart
Last 7 days
-7.0%
Last 30 days
0.0%
Last 90 days
3.5%
Trailing 12 Months
-27.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 15.1B | 10.7B | 9.1B | 6.8B |
2022 | 22.6B | 23.0B | 21.4B | 19.3B |
2021 | 2.7B | 7.0B | 11.8B | 18.5B |
2020 | 52.2M | 106.1M | 246.1M | 803.0M |
2019 | 122.1M | 106.3M | 81.6M | 60.2M |
2018 | 204.5M | 192.3M | 191.6M | 135.1M |
2017 | 132.8M | 157.1M | 181.5M | 205.8M |
2016 | 0 | 0 | 0 | 108.4M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 15, 2024 | hoge stephen | sold | -1,575,300 | 105 | -15,000 | president |
Apr 10, 2024 | afeyan noubar | sold | -1,606,860 | 107 | -15,000 | - |
Apr 08, 2024 | mock james m | sold | -71,859 | 101 | -705 | chief financial officer |
Apr 05, 2024 | mock james m | acquired | - | - | 1,453 | chief financial officer |
Apr 03, 2024 | afeyan noubar | sold | -1,525,270 | 101 | -15,000 | - |
Mar 27, 2024 | afeyan noubar | sold | -1,635,860 | 109 | -15,000 | - |
Mar 20, 2024 | afeyan noubar | sold | -1,535,820 | 102 | -15,000 | - |
Mar 15, 2024 | hoge stephen | sold | -1,547,550 | 103 | -15,000 | president |
Mar 13, 2024 | afeyan noubar | sold | -1,628,030 | 108 | -15,000 | - |
Mar 08, 2024 | klinger shannon thyme | sold | -53,883 | 99.0509 | -544 | chief legal officer |
Which funds bought or sold MRNA recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 15, 2024 | JANICZEK WEALTH MANAGEMENT, LLC | reduced | -84.03 | -9,810 | 2,025 | -% |
Apr 15, 2024 | CX Institutional | added | 24.88 | 79,864 | 316,078 | 0.01% |
Apr 15, 2024 | EXCHANGE TRADED CONCEPTS, LLC | reduced | -12.68 | -85,701 | 1,244,940 | 0.03% |
Apr 15, 2024 | TB Alternative Assets Ltd. | new | - | 6,382,940 | 6,382,940 | 1.60% |
Apr 15, 2024 | Chicago Capital, LLC | reduced | -9.15 | -5,691 | 208,325 | 0.01% |
Apr 15, 2024 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | reduced | -11.83 | -68,422 | 1,170,030 | -% |
Apr 15, 2024 | Sunbelt Securities, Inc. | reduced | -1.76 | 11,870 | 237,522 | 0.03% |
Apr 15, 2024 | THOMPSON INVESTMENT MANAGEMENT, INC. | added | 100 | 210 | 409 | -% |
Apr 15, 2024 | Concurrent Investment Advisors, LLC | new | - | 215,310 | 215,310 | 0.01% |
Apr 15, 2024 | Legato Capital Management LLC | added | 73.5 | 929,873 | 2,012,390 | 0.24% |
Unveiling Moderna Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Moderna Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 39.7B | 6.8B | -8.41 | 5.79 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.5B | 1.8B | -42.01 | 10.12 | ||||
BMRN | 17.2B | 2.4B | 102.31 | 7.09 | ||||
INCY | 11.9B | 3.7B | 20 | 3.23 | ||||
MID-CAP | ||||||||
APLS | 6.2B | 396.6M | -11.82 | 15.75 | ||||
BBIO | 4.4B | - | -6.81 | 60.35 | ||||
AXSM | 3.3B | 270.6M | -13.62 | 12.04 | ||||
ARWR | 2.9B | 240.7M | -9.88 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.95 | 3.88 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 25.63 | 4.6 | ||||
NVAX | 557.0M | 983.7M | -1.02 | 0.57 | ||||
CRBP | 432.8M | 881.7K | -9.7 | 466.16 | ||||
INO | 225.3M | 4.9M | -1.67 | 46.29 | ||||
IBIO | 6.8M | 2.1M | -0.25 | 2.14 |
Moderna Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | 53.5% | 2,811,000 | 1,831,000 | 344,000 | 1,862,000 | 5,084,000 | 3,364,000 | 4,749,000 | 6,066,000 | 7,211,000 | 4,969,000 | 4,354,000 | 1,937,000 | 571,000 | 157,000 | 67,000 | 8,000 | 14,055 | 17,046 | 13,083 | 16,025 | 35,421 |
Costs and Expenses | -27.0% | 2,805,000 | 3,843,000 | 2,211,000 | 2,228,000 | 3,504,000 | 2,198,000 | 2,302,000 | 1,839,000 | 1,801,000 | 1,411,000 | 1,292,000 | 671,000 | 846,000 | 392,000 | 189,000 | 139,000 | - | - | - | - | - |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 393,027 | 188,478 | 139,251 | 144,611 | 147,810 | 156,792 | 157,666 | 188,452 |
S&GA Expenses | 6.3% | 470,000 | 442,000 | 332,000 | 305,000 | 375,000 | 278,000 | 211,000 | 268,000 | 201,000 | 168,000 | 121,000 | 77,000 | 79,000 | 48,000 | 37,000 | 24,000 | 26,087 | 28,173 | 28,487 | 27,253 | 38,023 |
R&D Expenses | 21.2% | 1,406,000 | 1,160,000 | 1,148,000 | 1,131,000 | 1,211,000 | 820,000 | 710,000 | 554,000 | 648,000 | 521,000 | 421,000 | 401,000 | 759,000 | 344,000 | 152,000 | 115,000 | 117,645 | 119,637 | 128,305 | 130,413 | 150,429 |
EBITDA Margin | -Infinity% | -0.57* | - | 0.11* | 0.36* | 0.52* | 0.64* | 0.70* | 0.73* | 0.73* | 0.66* | 0.56* | 0.25* | -0.88* | - | - | - | - | - | - | - | - |
Income Taxes | -108.8% | -147,000 | 1,672,000 | -369,000 | -384,000 | 190,000 | 174,000 | 277,000 | 572,000 | 542,000 | 219,000 | 283,000 | 39,000 | 2,000 | 1,000 | - | - | -474 | -178 | -324 | -24.00 | 168 |
Earnings Before Taxes | 103.6% | 70,000 | -1,958,000 | -1,749,000 | -305,000 | 1,655,000 | 1,217,000 | 2,474,000 | 4,229,000 | 5,410,000 | 3,552,000 | 3,063,000 | 1,260,000 | -271,000 | -232,000 | -117,000 | -124,000 | -123,743 | -123,393 | -135,264 | -132,600 | -141,258 |
EBT Margin | -122.8% | -0.58* | -0.26* | 0.08* | 0.33* | 0.50* | 0.62* | 0.68* | 0.72* | 0.72* | 0.64* | 0.54* | 0.23* | - | - | - | - | - | - | - | - | - |
Net Income | 106.0% | 217,000 | -3,630,000 | -1,380,000 | 79,000 | 1,465,000 | 1,043,000 | 2,197,000 | 3,657,000 | 4,868,000 | 3,333,000 | 2,780,000 | 1,221,000 | -273,000 | -233,000 | -117,000 | -124,000 | -123,269 | -123,215 | -134,940 | -132,576 | -141,426 |
Net Income Margin | -81.2% | -0.69* | -0.38* | 0.11* | 0.32* | 0.43* | 0.55* | 0.61* | 0.65* | 0.66* | 0.60* | 0.50* | 0.22* | - | - | - | - | - | - | - | - | - |
Free Cashflow | 123.1% | 402,000 | -1,740,000 | -1,149,000 | -1,338,000 | 1,570,000 | 163,000 | 217,000 | 2,631,000 | 3,190,000 | 3,177,000 | 4,033,000 | 2,936,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -5.3% | 18,426 | 19,450 | 21,884 | 24,125 | 25,858 | 26,056 | 26,043 | 27,609 | 24,669 | 20,923 | 16,153 | 12,694 | 7,337 | 4,651 | 3,486 | 2,068 | 1,589 | 1,591 | 1,685 | 1,806 | 1,962 |
Current Assets | -4.4% | 10,325 | 10,799 | 10,599 | 12,122 | 13,431 | 14,297 | 13,563 | 16,350 | 16,071 | 13,425 | 10,969 | 11,703 | 6,298 | 3,577 | 2,797 | 1,250 | 1,129 | 1,094 | 1,097 | 1,141 | 1,563 |
Cash Equivalents | -0.9% | 2,907 | 2,932 | 3,801 | 3,441 | 3,205 | 3,027 | 2,873 | 5,048 | 6,848 | 5,550 | 5,603 | 5,442 | 2,636 | 1,506 | 1,762 | 392 | 248 | 174 | 152 | 503 | 670 |
Inventory | -58.5% | 202 | 487 | 715 | 732 | 949 | 2,077 | 1,921 | 1,942 | 1,441 | 965 | 643 | 494 | 47.00 | - | - | - | - | - | - | - | - |
Net PPE | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 204 | 209 | 213 | 212 |
Liabilities | -23.7% | 4,572 | 5,995 | 4,935 | 5,262 | 6,735 | 8,064 | 8,058 | 10,534 | 10,524 | 10,799 | 9,449 | 8,856 | 4,776 | 1,891 | 539 | 427 | 415 | 339 | 347 | 360 | 432 |
Current Liabilities | -31.2% | 3,015 | 4,385 | 3,123 | 3,499 | 4,923 | 6,807 | 6,812 | 9,238 | 9,128 | 9,957 | 8,840 | 8,441 | 4,389 | 1,474 | 162 | 135 | 143 | 148 | 162 | 159 | 223 |
Shareholder's Equity | 3.0% | 13,854 | 13,455 | 16,949 | 18,863 | 19,123 | 17,992 | 17,985 | 17,075 | 14,145 | 10,124 | 6,704 | 3,838 | 2,561 | 2,760 | 2,947 | 1,641 | 1,175 | 1,248 | 1,335 | 1,442 | 1,530 |
Retained Earnings | 1.6% | 13,606 | 13,389 | 17,019 | 18,399 | 18,320 | 16,855 | 15,812 | 13,615 | 9,958 | 5,090 | 1,757 | -1,023 | -2,244 | -1,970 | -1,737 | -1,620 | -1,496 | -1,369 | -1,246 | -1,111 | -1,006 |
Additional Paid-In Capital | 33.9% | 371 | 277 | 193 | 731 | 1,173 | 1,488 | 2,413 | 3,644 | 4,211 | 5,003 | 4,931 | 4,860 | 4,802 | 4,726 | 4,676 | 3,268 | 2,669 | 2,618 | 2,582 | 2,557 | 2,538 |
Shares Outstanding | 0.3% | 382 | 381 | 381 | 384 | 385 | 396 | 399 | 402 | 403 | 402 | 401 | 400 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 40,200 | - | - | - | 48,800 | - | - | - | 80,800 | - | - | - | 25,250 | - | - | - | 3,380 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 138.9% | 622 | -1,600 | -915 | -1,225 | 1,662 | 252 | 304 | 2,763 | 3,310 | 3,276 | 4,063 | 2,971 | 1,264 | 893 | -24.00 | -106 | -99.05 | -107 | -108 | -144 | -91.02 |
Share Based Compensation | 2.6% | 79.00 | 77.00 | 74.00 | 75.00 | 62.00 | 70.00 | 50.00 | 44.00 | 37.00 | 40.00 | 35.00 | 30.00 | 26.00 | 22.00 | 25.00 | 20.00 | 20.00 | 21.00 | 21.00 | 18.00 | 32.00 |
Cashflow From Investing | -168.2% | -538 | 789 | 1,944 | 2,011 | -1,048 | 945 | -1,152 | -3,921 | -1,138 | -3,327 | -3,878 | -180 | -190 | -1,179 | 13.00 | -316 | 130 | 113 | -246 | -11.76 | 6.00 |
Cashflow From Financing | -87.9% | -109 | -58.00 | -668 | -542 | -438 | -1,041 | -1,327 | -642 | -873 | -2.00 | -24.00 | 26.00 | 44.00 | 30.00 | 1,381 | 578 | 32.00 | 16.00 | 4.00 | 0.00 | 576 |
Buy Backs | 100.0% | - | -1.00 | 628 | 526 | 402 | 1,006 | 1,298 | 623 | 857 | - | - | - | - | - | - | - | - | - | - | - | - |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenue: | |||
Total revenue | $ 6,848 | $ 19,263 | $ 18,471 |
Operating expenses: | |||
Cost of sales | 4,693 | 5,416 | 2,617 |
Research and development | 4,845 | 3,295 | 1,991 |
Selling, general and administrative | 1,549 | 1,132 | 567 |
Total operating expenses | 11,087 | 9,843 | 5,175 |
(Loss) income from operations | (4,239) | 9,420 | 13,296 |
Interest income | 421 | 200 | 18 |
Other expense, net | (124) | (45) | (29) |
(Loss) income before income taxes | (3,942) | 9,575 | 13,285 |
Provision for income taxes | 772 | 1,213 | 1,083 |
Net (loss) income | $ (4,714) | $ 8,362 | $ 12,202 |
(Loss) earnings per share: | |||
Basic (in usd per share) | $ (12.33) | $ 21.26 | $ 30.31 |
Diluted (in usd per share) | $ (12.33) | $ 20.12 | $ 28.29 |
Weighted average common shares used in calculation of (loss) earnings per share: | |||
Basic (in shares) | 382 | 394 | 403 |
Diluted (in shares) | 382 | 416 | 431 |
Net product sales | |||
Revenue: | |||
Total revenue | $ 6,671 | $ 18,435 | $ 17,675 |
Other revenue | |||
Revenue: | |||
Total revenue | $ 177 | $ 828 | $ 796 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 2,907 | $ 3,205 |
Investments | 5,697 | 6,697 |
Accounts receivable, net | 892 | 1,385 |
Inventory | 202 | 949 |
Prepaid expenses and other current assets | 627 | 1,195 |
Total current assets | 10,325 | 13,431 |
Investments, non-current | 4,677 | 8,318 |
Property, plant and equipment, net | 1,945 | 2,018 |
Right-of-use assets, operating leases | 713 | 121 |
Deferred tax assets | 81 | 982 |
Other non-current assets | 685 | 988 |
Total assets | 18,426 | 25,858 |
Current liabilities: | ||
Accounts payable | 520 | 487 |
Accrued liabilities | 1,798 | 2,101 |
Deferred revenue | 568 | 2,038 |
Income taxes payable | 63 | 48 |
Other current liabilities | 66 | 249 |
Total current liabilities | 3,015 | 4,923 |
Deferred revenue, non-current | 83 | 673 |
Operating lease liabilities, non-current | 643 | 92 |
Financing lease liabilities, non-current | 575 | 912 |
Other non-current liabilities | 256 | 135 |
Total liabilities | 4,572 | 6,735 |
Commitments and contingencies (Note 11) | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001; 162 shares authorized as of December 31, 2023 and 2022; no shares issued or outstanding at December 31, 2023 and 2022 | 0 | 0 |
Common stock, par value $0.0001; 1,600 shares authorized as of December 31, 2023 and 2022; 382 and 385 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 0 | 0 |
Additional paid-in capital | 371 | 1,173 |
Accumulated other comprehensive loss | (123) | (370) |
Retained earnings | 13,606 | 18,320 |
Total stockholders’ equity | 13,854 | 19,123 |
Total liabilities and stockholders’ equity | $ 18,426 | $ 25,858 |